DR. KENNETH WIDDER, M.D.
Medical Practice at El Camino Real, Rancho Santa Fe, CA
License number
California G46485
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
16231 El Camino Real, Rancho Santa Fe, CA 92067
Phone
(619) 507-9827
Professional information
Emulsions As Contrast Agents And Method Of Use
US Patent:
5716597, Feb 10, 1998
Filed:
Jun 4, 1993
Appl. No.:
8/072535
Inventors:
Rolf Lohrmann - La Jolla CA
Kenneth J. Widder - Rancho Santa Fe CA
Ashwin M. Krishnan - San Diego CA
Dung Kevin Hong - San Diego CA
Jialun Meng - San Diego CA
Kenneth J. Widder - Rancho Santa Fe CA
Ashwin M. Krishnan - San Diego CA
Dung Kevin Hong - San Diego CA
Jialun Meng - San Diego CA
Assignee:
Molecular Biosystems, Inc. - San Diego CA
International Classification:
A61K 4900, B01J 1300
US Classification:
424 95
Abstract:
This invention relates to an oil-in-water emulsion that is of a water-insoluble gas-forming chemical and a stabilizer. The emulsion being capable of forming microbubbles of gas upon application of ultrasonic energy. This composition allows for site specific imaging as the image enhancing microbubbles can be released upon the application of ultrasonic energy at the specific location where the image is desired.
Emulsions As Contrast Agents And Method Of Use
US Patent:
5536489, Jul 16, 1996
Filed:
May 12, 1995
Appl. No.:
8/439693
Inventors:
Rolf Lohrmann - La Jolla CA
Kenneth J. Widder - Rancho Santa Fe CA
Ashwin M. Krishnan - San Diego CA
Dung K. Hong - San Diego CA
Jialun Meng - San Diego CA
Kenneth J. Widder - Rancho Santa Fe CA
Ashwin M. Krishnan - San Diego CA
Dung K. Hong - San Diego CA
Jialun Meng - San Diego CA
Assignee:
Molecular Biosystems, Inc. - San Diego CA
International Classification:
A61B 812
US Classification:
424 952
Abstract:
This invention relates to an oil-in-water emulsion that is of a water-insoluble gas-forming chemical and a stabilizer. The emulsion being capable of forming microbubbles of gas upon application of ultrasonic energy. This composition allows for site specific imaging as the image enhancing microbubbles can be released upon the application of ultrasonic energy at the specific location where the image is desired.
Transmucosal Delivery Of Proton Pump Inhibitors
US Patent:
2004000, Jan 8, 2004
Filed:
Jan 27, 2003
Appl. No.:
10/353143
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Warren Hall - San Diego CA, US
Kay Olmstead - San Diego CA, US
Warren Hall - San Diego CA, US
Kay Olmstead - San Diego CA, US
International Classification:
A61K031/4439, A61K009/24
US Classification:
514/338000, 424/471000
Abstract:
The present invention relates to pharmaceutical compositions and methods for transmucosal delivery of proton pump inhibitors. In one embodiment, the pharmaceutical composition of the present invention comprises a core which comprises an antacid, and an outer layer surrounding the core. The outer layer contains a therapeutically effective amount of a proton pump inhibitor. In another embodiment, the pharmaceutical composition of the present invention comprises an outer layer which comprising a unidirectional film, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. In yet another embodiment, the pharmaceutical composition of the present invention is a unidirectional tablet for delivery of a proton pump inhibitor across the oral mucosa. In this embodiment, the pharmaceutical composition contains an outer layer which contains a pharmaceutically acceptable water impermeable layer, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor.
Method Of Treatment Of Cardiac And/Or Renal Failure Using A Calcium Channel Blocker And An Angiotensin Converting Enzyme Inhibitor Or An Angiotensin Ii Receptor Blocker
US Patent:
2006005, Mar 16, 2006
Filed:
Aug 23, 2005
Appl. No.:
11/209463
Inventors:
Howard Dittrich - San Diego CA, US
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
International Classification:
A61K 31/455, A61K 31/4439
US Classification:
514338000, 514355000
Abstract:
Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.
Method Of Improved Diuresis In Individuals With Impaired Renal Function
US Patent:
7579331, Aug 25, 2009
Filed:
Apr 23, 2004
Appl. No.:
10/830617
Inventors:
Kenneth J. Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Howard C. Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
Lauren Otsuki - San Diego CA, US
Howard C. Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
Assignee:
Novacardia, Inc. - San Diego CA
International Classification:
A61K 31/70
US Classification:
514 45
Abstract:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.
Methods, Assays And Compositions For Treating Retinol-Related Diseases
US Patent:
2012020, Aug 9, 2012
Filed:
May 27, 2011
Appl. No.:
13/118207
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Jay Lichter - San Diego CA, US
Jay Lichter - San Diego CA, US
Assignee:
ReVision Therapeutics, Inc. - San Diego CA
International Classification:
A61K 31/167, A61P 27/02
US Classification:
514617
Abstract:
Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.
Method Of Treatment Of Disease Using An Adenosine A1 Receptor Antagonist And An Aldosterone Inhibitor
US Patent:
2009025, Oct 8, 2009
Filed:
Jun 16, 2009
Appl. No.:
12/485797
Inventors:
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Howard C. Dittrich - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Howard C. Dittrich - San Diego CA, US
International Classification:
A61K 31/585, A61K 31/522, A61P 9/00, A61P 13/12, A61P 9/04, A61P 9/12, A61P 9/10
US Classification:
514171, 514173, 51426323, 51426324
Abstract:
Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine Areceptor antagonist (AARA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.
Modulators Of Retinol-Retinol Binding Protein (Rbp)-Transthyretin (Ttr) Complex Formation
US Patent:
7432307, Oct 7, 2008
Filed:
Nov 4, 2005
Appl. No.:
11/267395
Inventors:
Nathan L. Mata - La Jolla CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Jay Lichter - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Jay Lichter - San Diego CA, US
Assignee:
Sirion Therapeutics, Inc. - Tampa FL
International Classification:
A61K 31/07
US Classification:
514725, 514613, 514699, 514741, 514912
Abstract:
Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
Modulators Of Retinol-Retinol Binding Protein (Rbp)-Transthyretin (Ttr) Complex Formation
US Patent:
2012023, Sep 20, 2012
Filed:
Sep 13, 2011
Appl. No.:
13/231890
Inventors:
Nathan L. Mata - La Jolla CA, US
Yun Han - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Jay Lichter - Rancho Santo Fe CA, US
Yun Han - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Jay Lichter - Rancho Santo Fe CA, US
Assignee:
ReVision Therapeutics, Inc. - San Diego CA
International Classification:
A61K 31/167, A61P 27/02
US Classification:
514613
Abstract:
Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
Methods And Compositions For Treating Ophthalmic Conditions With Retinyl Derivatives
US Patent:
8314152, Nov 20, 2012
Filed:
Jun 10, 2005
Appl. No.:
11/150641
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Jay Lichter - San Diego CA, US
Nathan L. Mata - La Jolla CA, US
Jay Lichter - San Diego CA, US
Nathan L. Mata - La Jolla CA, US
Assignee:
Acucela, Inc. - Seattle WA
International Classification:
A01N 33/18, A01N 33/24, A61K 31/12
US Classification:
514676
Abstract:
Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.